This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) ~~Compounds~~ A compound of ~~the general~~ formula I



I,

in which

R^1	is H or A,
$R^{2'}$, $R^{2''}$, $R^{2'''}$	are each, independently of one another, H, A, OH, OCH_3, OCF_3, Hal, CN, $COOR^1$, $CONR^1$ or NO_2,
R^3	is A, Ar or A-Ar,
R^4	is H or A,
A	is unbranched or branched alkyl having 1-10 carbon atoms, in which one or two CH_2 groups may be replaced by O or S atoms and/or by -CH=CH- groups and/or 1-7 H atoms may ~~also~~ be replaced by F,
Ar	is phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR^4, $N(R^4)_2$, NO_2, CN, $COOR^4$, $CON(R^4)_2$, NR^4COA, $NR^4CON(R^4)_2$, NR^4SO_2A, COR^4, $SO_2N(R^4)_2$ or SO_2A,
A-Ar	is arylalkyl, where A and Ar have one of the above-mentioned meanings,
Hal	is F, Cl, Br or I, and
n	is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10,

~~and solvates, stereoisomers and pharmaceutically usable derivatives, thereof, including mixtures thereof in all ratios~~ or a pharmaceutically acceptable salt thereof.

2. (Currently Amended) ~~Compounds~~ A compound according to Claim 1, in which R^1 is hydrogen~~, and solvates, stereoisomers and pharmaceutically usable derivatives thereof, including mixtures thereof in all ratios~~.

3. (Currently Amended) ~~Compounds~~ A compound according to Claim 1, in which $R^{2'}$, $R^{2''}$, $R^{2'''}$ are hydrogen~~, and solvates, stereoisomers and pharmaceutically usable derivatives thereof, including mixtures thereof in all ratios~~.

4. (Currently Amended) ~~Compounds~~ A compound according to ~~claim 1~~ claim 1, in which R^3 is n-propyl, i-propyl, n-butyl, 2,2,2-trifluoroethyl, phenyl, benzyl or 2-nitrophenylmethyl~~, and solvates, stereoisomers and pharmaceutically usable derivatives thereof, including mixtures thereof in all ratios~~.

5. (Currently Amended) ~~Compounds~~ A compound according to claim 1, in which n is 1~~, and solvates, stereoisomers and pharmaceutically usable derivatives thereof, including mixtures thereof in all ratios~~.

6. (Currently Amended) ~~Compounds~~ A compound according to Claim 1, which is ~~selected from the group consisting of~~

N-[4-(1-benzylpiperidin-4-yloxy)phenyl]-C-phenylmethanesulfonamide,

N-[4-(1-benzylpiperidin-4-yloxy)phenyl]-C-[2-nitrophenyl]methanesulfonamide,

N-[4-(1-benzylpiperidin-4-yloxy)phenyl]benzenesulfonamide,

N-[4-(1-benzylpiperidin-4-yloxy)phenyl]- 2-propanesulfonamide,

N-[4-(1-benzylpiperidin-4-yloxy)phenyl]-1-butanesulfonamide,

N-[4-(1-benzylpiperidin-4-yloxy)phenyl]-1-propanesulfonamide, or

N-[4-(1-benzylpiperidin-4-yloxy)phenyl]-1-2,2,2-trifluoroethanesulfonamide,

~~and solvates, stereoisomers and pharmaceutically usable derivatives thereof, including mixtures thereof in all ratios~~ or a pharmaceutically acceptable salt thereof.

7. (Currently Amended) ~~Process for the preparation of compounds of the~~ A process for preparing a compound of formula I according to claim1 ~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof, characterised in that~~ or a pharmaceutically acceptable salt thereof, comprising

a) reacting a compound of ~~the~~ formula V



V,

in which R is a nucleophilic leaving group ~~usually employed~~ suitable for nucleophilic ~~substitutions~~ substitution on an aromatic ~~compounds, is reacted~~ compound with a compound of ~~the~~ formula VI



VI,

in which $R^{2'}$, $R^{2''}$, $R^{2'''}$ and n are as defined ~~in Claim 1~~ for the compound of formula I, giving a compound of ~~the~~ formula IV



IV,

b) ~~the resultant phenoxy-piperidine of the~~ converting the compound of formula IV ~~is converted~~ by hydrogenation and optionally alkylation into a compound of ~~the~~ formula II



II,

in which R^1 is as defined ~~in Claim 1~~ for the compound of formula I, which is then

c) reacted ~~further~~ with a compound of the formula III

Error! Bookmark not defined. III,

in which R3 is as defined ~~in Claim 1~~ for the compound of formula I, and L is a nucleophilic leaving group ~~known per se~~, giving a compound of ~~the~~ formula I,

and optionally a protecting group is subsequently cleaved off,

and/or a base or acid of ~~the~~ a compound of formula I is converted into one of its salts.

8. (Cancelled)

9. (Cancelled)

10. (Cancelled)

11. (Currently Amended) ~~Medicaments~~ A pharmaceutical composition comprising ~~at least one~~ a compound of ~~the~~ formula I according to claim 1, ~~and/or~~ or a pharmaceutically ~~usable derivatives, solvates and stereoisomers~~ acceptable salt thereof, ~~including mixtures thereof in all ratios, according to claim 1~~, and ~~optionally excipients~~ a pharmaceutically acceptable excipient and/or ~~adjuvants~~ adjuvant.

12. (Currently Amended) ~~Medicaments~~ A pharmaceutical composition according to claim 11, further comprising ~~comprising at least one compound of the formula I and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, according to, and~~ at least one further ~~medicament~~ pharmaceutically active ingredient.

13. (Withdrawn and Currently Amended) ~~Use of compounds according to claim 1 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament~~ A method for the prophylaxis or treatment of ~~diseases~~ a disease in which the binding of ~~one or more active ingredients present in the said medicament~~ a compound of formula I according to claim 1 or a pharmaceutically acceptable salt thereof to a nicotinic and/or muscarinic acetylcholine receptor ~~receptors~~ leads to an improvement in the clinical picture comprising administering to a patient in need thereof an effective amount of the compound of formula I or a pharmaceutically acceptable salt thereof.

14. (Withdrawn and Currently Amended) ~~Use of compounds according to claim 1 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament~~ A method for the prophylaxis or treatment of schizophrenia, depression, an anxiety ~~states~~ state, dementia, Alzheimer's disease, Lewy bodies dementia, a neurodegenerative ~~diseases~~ disease, Parkinson's disease, Huntington's disease, Tourette's syndrome, a learning ~~and~~ or memory ~~impairments~~ impairment, age-related memory impairment, amelioration of withdrawal

symptoms in nicotine dependence, ~~strokes~~ stroke or brain damage by a toxic ~~compounds~~ compound, comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition according to claim 11.

15. (Cancelled)

16. (Currently Amended) ~~Process for the preparation of~~ A process for preparing a pharmaceutical composition ~~comprising at least one compound~~ according to ~~claim 1~~ claim 11, comprising converting said composition into a suitable dosage form together with at least one solid, liquid or semi-liquid excipient or adjuvant.

17. (Withdrawn and Currently Amended) ~~Set (kit) consisting of~~ A set or kit comprising separate packs of

(a) an effective amount of a compound of ~~the~~ formula I according to ~~and/or~~ claim 1 or a pharmaceutically ~~usable derivatives, solvates and stereoisomers~~ acceptable salt thereof, ~~including mixtures thereof in all ratios,~~ and

(b) an effective amount of a further ~~medicament~~ pharmaceutically active ingredient.

18. (Withdrawn and Currently Amended) ~~Use of compounds of the formula I and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, according to claim 1, for the preparation of a medicament for the prophylaxis or treatment of schizophrenia, depression, anxiety states, dementia, Alzheimer's disease, Lewy bodies dementia, neurodegenerative diseases, Parkinson's disease, Huntington's disease, Tourette's syndrome, learning and memory impairments, age-related memory impairment, amelioration of withdrawal symptoms in nicotine dependence, strokes or brain damage by toxic compounds, in combination with at least one further medicament active ingredient~~ A method for the prophylaxis or treatment of schizophrenia, depression, an anxiety state, dementia, Alzheimer's disease, Lewy bodies dementia, a neurodegenerative disease, Parkinson's disease, Huntington's disease, Tourette's syndrome, a learning or memory impairment, age-related memory impairment, amelioration of withdrawal symptoms in nicotine dependence, stroke or brain damage by a toxic compound, comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition according to claim 12.

19-20. (Cancelled)

21. (New) An isolated stereoisomer of a compound of formula I according to claim 1.

22. (New) A mixture of stereoisomers of a compound of formula I according to claim 1.

23. (New) A compound of formula I



I,

in which

R^1	is H or A,
$R^{2'}$, $R^{2''}$, $R^{2'''}$	are each, independently of one another, H, A, OH, OCH_3, OCF_3, Hal, CN, $COOR^1$, $CONR^1$ or NO_2,
R^3	is A, Ar or A-Ar,
R^4	is H or A,
A	is unbranched or branched alkyl having 1-10 carbon atoms, in which one or two CH_2 groups may be replaced by O or S atoms and/or by -CH=CH- groups and/or 1-7 H atoms may be replaced by F,
Ar	is phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR^4, $N(R^4)_2$, NO_2, CN, $COOR^4$, $CON(R^4)_2$, NR^4COA, $NR^4CON(R^4)_2$, NR^4SO_2A, COR^4, $SO_2N(R^4)_2$ or SO_2A,
A-Ar	is arylalkyl, where A and Ar have one of the above-mentioned meanings,
Hal	is F, Cl, Br or I, and
n	is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10,

or a pharmaceutically acceptable salt or solvate thereof.

24. (New) A compound according to claim 23, wherein the solvate is a mono- or dihydrate or alcoholate.